What's new

Welcome to fokve | Welcome My Forum

Join us now to get access to all our features. Once registered and logged in, you will be able to create topics, post replies to existing threads, give reputation to your fellow members, get your own private messenger, and so, so much more. It's also quick and totally free, so what are you waiting for?

Achieving Reliable Cross-Laboratory Flow Cytometry Instrument Standardization

Hoca

Administrator
Staff member
Joined
Apr 6, 2025
Messages
83
Reaction score
0
Points
0
Flow cytometry has become a key analytical technique in clinical trials. Through its multiparametric analysis, single-cell resolution, and high-throughput evaluation capabilities, flow cytometry can provide invaluable insights in therapeutic areas from autoimmunity and oncology to infectious diseases. One of the biggest challenges with the technique, however, is ensuring data consistency across laboratories in multi-center flow cytometry studies.

In such multi-center or global clinical trials, the use of different instruments and operators at each site introduces significant variability in flow cytometry readouts, making it challenging to compare results across locations. For drug developers, the lack of standardized data is both a logistical and a scientific hurdle. When results from different sites can’t be directly compared, it may lead to delays, increased costs, and the need for re-analysis or additional testing to achieve reliable data. Moreover, data variability compromises the reliability and reproducibility of results, undermining confidence in cross-site findings.

While some standardization efforts—such as shipping consistent reagents (antibodies and beads) to each site—can help align results, they are typically time-consuming, costly, and may only be partially effective. Even with consistent reagents, differences in staining protocols, instrument calibration, and operator technique can still result in variations, limiting researchers’ ability to achieve truly comparable data across study sites.

A novel method to align flow cytometry instruments


To address some of these challenges, we tested a robust, cost-efficient method for transferring a flow cytometry set-up across five different laboratories to achieve more consistent data.

First, polystyrene microbeads (BD
™
CompBeads) were stained with a set of CD4 antibodies and then lyophilized (freeze-dried) to make them stable at room temperature for 18 months. The stable, pre-stained beads were then shipped to the five sites where we tested their consistency across the locations.

Once the beads arrived, each laboratory calibrated the bead to the target values on their harmonized instruments. Following this calibration, all instruments demonstrated similar performance characteristics (Figure 1), effectively creating a unified ‘fleet’ of instruments across locations.

Thermo Fisher March 2025 Translational MedicineTutorial Figure 1

Figure 1. Graphs demonstrating alignment across all 15 instruments from five different sites on the 18 different lyophilized beads (covering the 18 assorted colors of the flow cytometer). The instruments show an almost perfect alignment for both positive and negative signals. [Poster data presented at CYTO 2024.]

Evaluation of reagent stability across sites


Following the initial set-up and harmonization process, we conducted tests to confirm the performance consistency of the lyophilized beads after resuspension. To do this, we tested reagent stability at different time points across two of the participating sites. The beads were kept in the dark and on ice, and mean fluorescence intensity (MFI) readings were taken at 15 mins, 30 mins, and then at 1, 2, 4, 6, 8, 24, and 48 hours after resuspension. For each time point across each fluorochrome, we calculated the change in fluorescent signal relative to the 15-minute reading, giving a percentage similarity (Table 1A).

To assess long-term stability, we conducted the same tests a year after the beads were shipped (Table 1B). During both the initial testing and the one-year follow-up, results indicated that, while most dyes remained stable after resuspension, some fluorochromes were less stable, and so were replaced with more robust alternatives. We replaced the dyes BB700, APC, and APC-R700 with RB705, Alexa-647, and Alexa Fluor®-700, respectively, to create a new kit. The updated kit supported stable signal acquisition for up to 8 hours post-resuspension, facilitating consistent and reproducible data collection across sites and time points (Table 1C).

Cell Carta March 2025 Translational Medicine Tutorial Table 1a b c

Table 1: Stability of resuspended lyophilized beads over time. (A) Most of the reagents were stable up to 48 hours post-resuspension based on a 10% difference cutoff. However, the APC and PE-CF594 dyes showed limited stability, remaining effective for only 6 to 8 hours. BB700, APC-R700, and PE maintained stability for 24 to 48 hours but approached the limit by 48 hours. (B) After a year, these stability patterns were consistent. (C) For the dyes that were less stable, we identified alternatives and tested the new kit at 15 min, 30 min, and 1, 2, 4, 6, and 8 hours post resuspension. All the dyes tested displayed a stable signal for up to 8 hours. [Poster data published at CYTO 2024.]

Verification of shared assay alignment


While we achieved instrument harmonization across sites using lyophilized beads, further validation was needed to confirm such alignment is translated to assay performance on clinical specimens. To assess this, we aligned nine fluorescence parameters using the lyophilized beads, after which we tested the assay’s reproducibility by comparing 14 inter- and intra-site readouts from a reference sample with samples from three healthy donors.

Results indicated assay alignment, with readouts in the receiving laboratories having a coefficient of variation below our official criteria of 25% when compared to the reference laboratory, and a majority even below 10%. This level of consistency demonstrated successful assay alignment across all the active sites, as illustrated in Figure 2. These findings confirm that the harmonization achieved at the instrument level translated effectively into assay-level consistency, supporting cross-site data comparability.

Cell Carta March 2025 Translational Medicine Tutorial Figure 2

Figure 2: Graphs showing shared assay alignment. The representative overlay plots illustrate 14 intra- and inter-site readouts and show optimal alignment between all the instruments. We isolated a B-cell population (CD45+ CD3- CD19+ CD20+) and examined marker of interest labeled with an IgG4 antibody on monocytes. CD14, CD16/CD56 profile was used to observe overall monocytes. [Poster data published at CYTO 2024.]

A reliable, consistent, method for multi-site instrument alignment


Through the study, we showed that using lyophilized beads can enable multi-site instrument alignment. Overall, we found that this approach can deliver:

  • Maintained data quality and reliability: the beads remained effective up to 48 hours post-resuspension and performed comparably even after a year, helping ensure stable data throughout clinical studies;
  • Consistency across sites: the alignment of instruments and assays across sites standardized the analysis process, reducing data variability and allowing for more accurate data comparisons across locations;
  • Cost and time savings: the 18-month stability of the beads helped reduce shipping requirements and recalibrations, which can help lower cost and administrative demands for more streamlined study workflows.

Overall, by employing pre-stained, lyophilized beads for flow cytometry instrument alignment, researchers can reduce inter-laboratory variability, supporting more consistent and reliable clinical research and enhancing the cost-effectiveness of flow cytometry in global clinical trials.



Dominic Gagnon is the associate director of global flow cytometry at CellCarta.

The post Achieving Reliable Cross-Laboratory Flow Cytometry Instrument Standardization appeared first on GEN - Genetic Engineering and Biotechnology News.
 
Top Bottom